Argentina Spanish Localization: Certified Translation and Terminology Control
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Argentina’s language requirement is strict: all submission documents, labels and instructions for use (IFU) must be in Spanish, and documents in a foreign language must be accompanied by a certified (sworn/official) translation.
This is not a formality. The Spanish quality of the technical documentation directly affects review efficiency: terminology errors trigger deficiency letters, and can even lead the reviewer to question the product itself. The requirement runs through the translation requirements of Part III, Article 6 of GMC 25/21, the label language requirements of Annex IV, and the vigilance reports under Disposición ANMAT 8194/2023. Non-compliant Spanish in the label or IFU is, in itself, an explicit ground for rejection, which makes language planning a compliance issue rather than a translation vendor issue.
The economics of the requirement also argue for early investment. Sworn translation is a paid, scheduled service, and re-translating documents after a terminology error has been found in review costs more than translating them correctly once. Companies that treat Spanish localization as a one-time capital expenditure, done well at the start of market entry, systematically spend less than companies that treat it as a per-document operational cost discovered late.
2. Legal basis
| Regulatory instrument | Number | Publication date | Relevant provisions |
|---|---|---|---|
| MERCOSUR technical regulation for medical device registration | GMC/RES 25/21 | October 13, 2021 | Part III, Article 6 (translation requirements); Annex IV (label language) |
| Domestic implementing instrument | Disposición ANMAT 64/2025 | Published in the Official Gazette on January 13, 2025 | Language requirement provisions |
| IVD labeling requirements | Disposición ANMAT 2674/99 | 1999 | Label language provisions |
| Good technovigilance practices | Disposición ANMAT 8194/2023 | Published October 3, 2023, effective October 4, 2023 | Language requirements for vigilance reports |
Together the instruments make Spanish a lifecycle obligation rather than a submission formality: GMC 25/21 and Disposición ANMAT 64/2025 govern the registration file, Disposición ANMAT 2674/99 adds language duties for IVD labels, and Disposición ANMAT 8194/2023 extends the same requirement to the vigilance reports that the holder files for years after the certificate is granted.
The practical reading of this table is that no document family is exempt. A company that localizes only the registration dossier and leaves operational filings in another language has satisfied the smallest part of the obligation and left the recurring, permanent part untouched. The localization program should therefore be scoped to cover everything the Argentine market presence will ever produce, not just the submission package.
3. Expert insights
Insight 1: the language requirement spans the full lifecycle, not just the submission. Submission documents, labels, IFUs, vigilance reports, change justifications and promotional materials must all be in Spanish. Companies face the same language requirement when filing vigilance reports in ARGOS and import notifications in BONITA, so the translation capability built for the registration project becomes a permanent operating capability of the Argentine market presence.
Insight 2: a certified translation in Argentina means a sworn translator (traductor público). This is not an ordinary translation agency service, but a translation completed and signed by a qualified Argentine sworn translator. Machine translations and non-certified translations are not accepted, and a file that arrives with them is treated the same way as a file with a missing document.
Insight 3: terminological consistency matters more than linguistic elegance. Reviewers check whether the same concept uses the same term across the label, the IFU and the technical report. The recommended control is a company-internal Spanish glossary that fixes the key terms, including the product name, model nomenclature, warnings and performance parameters, and applies them uniformly across every document in the dossier and beyond.
The glossary should be treated as a controlled document in its own right, with a version history and a defined approval step, because it silently shapes every future translation. When a term is changed, the change must propagate to the label, the IFU and the technical report at the same time, or the very consistency the glossary exists to protect will be broken by the update itself. Assigning ownership of the glossary to the regulatory function, rather than to any single vendor, keeps this control inside the company as suppliers change.
4. Practical recommendations
- Commission key documents from an Argentine sworn translator. Give priority, for the 5 categories of CFS, authorization statement, technical report, label and IFU, to local regulatory translation rather than machine translation, and build the cost and lead time of sworn translation into the project budget from the outset.
- Build a company-internal Spanish terminology glossary. Fix the product names, models, warnings, performance parameters and clinical terms once, then apply the glossary uniformly across all documents, so each new translation inherits an established vocabulary instead of reinventing one.
- Subject labels and IFUs to local language review. Have a Spanish native speaker with a medical device background review the texts once, focusing on whether units, symbols and abbreviations follow local conventions.
- Bring language into change management. For any modification of a label or an IFU, the Spanish version must be updated in step, and versions in other languages must never fall out of sync with the Spanish text.
5. Verification checklist
- □ All submission documents provided in Spanish
- □ Translations of foreign-language documents completed and signed by an Argentine sworn translator
- □ Labels and IFU in Spanish with standardized terminology
- □ Company-internal Spanish terminology glossary established and applied across documents
- □ The same concept uses the same term across the label, the IFU and the technical report
- □ Spanish versions of operational documents such as vigilance reports and import notifications prepared
Regulatory information verified as of October 29, 2026.
In Argentina, GRZAN operates a wholly owned subsidiary that can serve as the registration holder and importer of record for foreign manufacturers, directly handling classification assessment, pathway selection, building the GMP and CFS documentation chain, Spanish-language localization of technical documentation and labeling, HELENA submissions and responses to deficiency letters, as well as BONITA import notifications, operation of the ARGOS vigilance system, change maintenance and planning for the 5-year renewal. For support with registration dossiers and conformity documentation for the Argentine market, contact the GRZAN regulatory team at info@grzanglobal.com.
The GRZAN regulatory team consists of professionals with many years of hands-on experience in international registrations, tracks the activity of regulatory authorities across markets on an ongoing basis, and applies a writing standard of conclusions first, traceable sources and verifiable figures to everything it publishes. For a market access plan tailored to a specific product in Argentina or the wider MERCOSUR region, the GRZAN regulatory team welcomes your enquiry at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us